¸¸¼º °ñ¼ö¼º ¹éÇ÷º´ ȯÀÚ¿¡¼ ÈÇпä¹ý¿¡ º´¿ëµÈ °¨¸¶ÀÎÅÍÆä·ÐÀÇ È¿°ú
The Additive Effect of Recombinant r-Interferon on the Chronic Myelogenous Leukemia Patients Under Conventional Chemotherapy
´ëÇÑÇ÷¾×ÇÐȸÁö 1988³â 23±Ç 2È£ p.373 ~ p.379
¹ÚÁ¾¿ø(Park Chong-Won) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹ÚűÙ(Park Tae-Keun) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÁÖö(Kim J.-C.) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÇÑÄ¡È(Han Chi-Hwa) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÃáÃß(Kim Choon-Choo) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èµ¿Áý(Kim Dong-Jip) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Gamma interferon has known to suppress normal as well as chronic myelogenous leukemia CFU-GM. We studied the therapeutic effect of recombinant r -lFN on the CML patinets under conventional chemotherapy, 29 patients with CML (chronic 18, advanced 11) were treated with recombinant r-IFN 0.2 §·/day (2¡¿106 IU/day) by daily subcutaneous injection for more than 6 months. Among 18 patients in chronic phase, 9 (50%) achieved complete hematological response and 8 (44%) showed partial responses. 4 (36%) out of 11 advanced disease responded partially.
In responding patients, the r-IFN reduced the requirment of hydroxyurea and prolonged the duration of responses.
The age and sex did not affect the response rate to the r-IFN therapy. But, there was tendency of increased response rate by early introduction of r-IFN to the chronic phase of CML. Although our observation period was short, our result indicated that r-IFN affect synergistically to the conventional chemotherapy for the patient with CML.
Å°¿öµå
KMID :
0366219880230020373
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
r-IFN affect synergistically to the conventional chemotherapy for the patient with CML